These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 23392467)

  • 1. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.
    Kreitchmann R; Best BM; Wang J; Stek A; Caparelli E; Watts DH; Smith E; Shapiro DE; Rossi S; Burchett SK; Hawkins E; Byroads M; Cressey TR; Mirochnick M
    J Acquir Immune Defic Syndr; 2013 May; 63(1):59-66. PubMed ID: 23392467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
    Mirochnick M; Best BM; Stek AM; Capparelli EV; Hu C; Burchett SK; Rossi SS; Hawkins E; Basar M; Smith E; Read JS;
    J Acquir Immune Defic Syndr; 2011 Apr; 56(5):412-9. PubMed ID: 21283017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
    Kiser JJ; Fletcher CV; Flynn PM; Cunningham CK; Wilson CM; Kapogiannis BG; Major-Wilson H; Viani RM; Liu NX; Muenz LR; Harris DR; Havens PL;
    Antimicrob Agents Chemother; 2008 Feb; 52(2):631-7. PubMed ID: 18025112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
    Le Tiec C; Barrail A; Goujard C; Taburet AM
    Clin Pharmacokinet; 2005; 44(10):1035-50. PubMed ID: 16176117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
    von Hentig N; Dauer B; Haberl A; Klauke S; Lutz T; Staszewski S; Harder S
    Eur J Clin Pharmacol; 2007 Oct; 63(10):935-40. PubMed ID: 17665183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of tenofovir during pregnancy and postpartum.
    Best BM; Burchett S; Li H; Stek A; Hu C; Wang J; Hawkins E; Byroads M; Watts DH; Smith E; Fletcher CV; Capparelli EV; Mirochnick M;
    HIV Med; 2015 Sep; 16(8):502-11. PubMed ID: 25959631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.
    Wang X; Boffito M; Zhang J; Chung E; Zhu L; Wu Y; Patterson K; Kashuba A; Tebas P; Child M; Mahnke L; Bertz R
    AIDS Patient Care STDS; 2011 Sep; 25(9):509-15. PubMed ID: 21770762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atazanavir exposure is effective during pregnancy regardless of tenofovir use.
    Colbers A; Hawkins D; Hidalgo-Tenorio C; van der Ende M; Gingelmaier A; Weizsäcker K; Kabeya K; Taylor G; Rockstroh J; Lambert J; Moltó J; Wyen C; Sadiq ST; Ivanovic J; Giaquinto C; Burger D;
    Antivir Ther; 2015; 20(1):57-64. PubMed ID: 24992294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.
    Benaboud S; Hirt D; Launay O; Pannier E; Firtion G; Rey E; Bouazza N; Foissac F; Chappuy H; Urien S; Tréluyer JM
    Antimicrob Agents Chemother; 2012 Feb; 56(2):857-62. PubMed ID: 22123690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.
    Conradie F; Zorrilla C; Josipovic D; Botes M; Osiyemi O; Vandeloise E; Eley T; Child M; Bertz R; Hu W; Wirtz V; McGrath D
    HIV Med; 2011 Oct; 12(9):570-9. PubMed ID: 21569187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
    Bifano M; Hwang C; Oosterhuis B; Hartstra J; Grasela D; Tiessen R; Velinova-Donga M; Kandoussi H; Sevinsky H; Bertz R
    Antivir Ther; 2013; 18(7):931-40. PubMed ID: 23963204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
    Dumond JB; Adams JL; Prince HM; Kendrick RL; Wang R; Jennings SH; Malone S; White N; Sykes C; Corbett AH; Patterson KB; Forrest A; Kashuba AD
    HIV Med; 2013 Aug; 14(7):401-9. PubMed ID: 23433482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.
    King JR; Yogev R; Jean-Philippe P; Graham B; Wiznia A; Britto P; Carey V; Hazra R; Acosta EP;
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4290-4. PubMed ID: 21670182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate.
    Bunupuradah T; Techasaensiri C; Keadpudsa S; Thammajaruk N; Srimuan A; Sahakijpicharn T; Prasitsuebsai W; Ananworanich J; Puthanakit T;
    Pediatr Infect Dis J; 2014 Dec; 33(12):e316-9. PubMed ID: 24983717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting.
    Calcagno A; Bonora S; Tettoni MC; D'Avolio A; Perri GD; Lanzafame M; Penco G
    J Acquir Immune Defic Syndr; 2009 Nov; 52(3):431-2. PubMed ID: 19858926
    [No Abstract]   [Full Text] [Related]  

  • 16. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
    Waters LJ; Moyle G; Bonora S; D'Avolio A; Else L; Mandalia S; Pozniak A; Nelson M; Gazzard B; Back D; Boffito M
    Antivir Ther; 2007; 12(5):825-30. PubMed ID: 17713166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
    Dailly E; Tribut O; Tattevin P; Arvieux C; Perré P; Raffi F; Jolliet P
    Eur J Clin Pharmacol; 2006 Jul; 62(7):523-6. PubMed ID: 16763827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
    Pruvost A; Negredo E; Théodoro F; Puig J; Levi M; Ayen R; Grassi J; Clotet B
    Antimicrob Agents Chemother; 2009 May; 53(5):1937-43. PubMed ID: 19273671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.
    Foissac F; Blanche S; Dollfus C; Hirt D; Firtion G; Laurent C; Treluyer JM; Urien S
    Br J Clin Pharmacol; 2011 Dec; 72(6):940-7. PubMed ID: 21649692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.